文献速递产科母胎医学

产前暴露于普伐他汀儿童的长期神经发育随访

Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero.
PubMed 文献 · Am J Obstet Gynecol · 2023-02-24

本研究为 obstetric-fetal pharmacology research centers network 普伐他汀与安慰剂试点试验的辅助随访队列,纳入40名儿童中的30名(普伐他汀组15名、安慰剂组15名),随访时间4.7年(四分位距2.5-6.9)。两组儿童体重指数百分位、并发症及儿童行为量表报告无差异,普伐他汀组一般平均概念能力评分较高(98.2±16.7 vs 89.7±11.0;P=.13),评分<85的频率较低(15.4% vs 35.7%;P=.38),均未达统计学显著。作者认为尽管受原试验样本量限制,未发现明确的长期神经发育安全信号。

要点

  • 产前暴露于普伐他汀的儿童在4.7年随访中未发现明确的长期神经发育安全信号。
  • 普伐他汀组一般平均概念能力评分为98.2±16.7,安慰剂组为89.7±11.0(P=.13)。
  • 普伐他汀组评分<85的频率为15.4%,安慰剂组为35.7%(P=.38)。

核心结论

  • 尽管数据受原试验样本量限制,妊娠期使用普伐他汀未发现明确的长期神经发育安全信号。
  • 作者认为有利的新生儿风险-获益分析支持继续在临床试验中使用普伐他汀进行研究。

研究设计与样本

  • 本研究为 obstetric-fetal pharmacology research centers network 普伐他汀与安慰剂试点试验的辅助随访队列研究(ClinicalTrials.gov;标识 NCT01717586)。
  • 原试验纳入40名儿童,本随访研究入组30名(普伐他汀组15名、安慰剂组15名)。
  • 因研究人数少,将10 mg和20 mg普伐他汀组合并为1组,并与安慰剂组比较。
  • 由认证且设盲的研究心理学家使用经验证的工具完成儿童运动、认知、情绪和行为评估,家长填写儿童行为量表。

主要发现

  • 随访时间为4.7年(四分位距2.5-6.9),普伐他汀组与安慰剂组儿童间无差异。
  • 两组儿童按性别和矫正年龄的体重指数百分位、体重指数百分位极端值发生率或其他医学或发育并发症报告均无差异。
  • 普伐他汀组无儿童在运动评估中受限,安慰剂组有2名(13.3%)行走困难、4名(26.7%)手部能力下降。
  • 普伐他汀组一般平均概念能力评分为98.2±16.7,安慰剂组为89.7±11.0(P=.13)。
  • 普伐他汀组评分<85(即低于均值1个标准差)的频率为15.4%,安慰剂组为35.7%(P=.38)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据受原试验样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia, especially before term, increases the risk of child neurodevelopmental adverse outcomes. Biological plausibility, preclinical studies, and pilot clinical trials conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Obstetric-Fetal Pharmacology Research Centers Network support the safety and use of pravastatin to prevent preeclampsia. OBJECTIVE: This study aimed to determine the effect of antenatal pravastatin treatment in high-risk pregnant individuals on their child's health, growth, and neurodevelopment. STUDY DESIGN: This was an ancillary follow-up cohort study of children born to mothers who participated in the Obstetric-Fetal Pharmacology Research Centers Network pilot trials of pravastatin vs placebo in individuals at high risk of preeclampsia (ClinicalTrials.gov; identifier NCT01717586). After obtaining written informed consent (and assent as appropriate), the parent was instructed to complete the Child Behavior Checklist. To assess the child's motor, cognitive, and developmental outcomes, a certified and blinded study psychologist completed child motor, cognitive, emotional, and behavioral assessments using validated tools. Given the small number of individuals in the studies, the 10- and 20-mg pravastatin groups were combined into 1 group, and the results of the pravastatin group were compared with that of the placebo group. RESULTS: Of 40 children born to mothers in the original trial, 30 (15 exposed in utero to pravastatin and 15 to placebo) were enrolled in this follow-up study. The time of follow-up, which was 4.7 years (interquartile range, 2.5-6.9), was not different between children in the pravastatin group and children in the placebo group. There was no difference in the child's body mass index percentiles per sex and corrected age, the rates of extremes of body mass index percentiles, or the report of any other medical or developmental complications between the 2 groups. No child born in the pravastatin group had any limitation in motor assessment compared with 2 children (13.3%) who walked with difficulty and 4 children (26.7%) who had reduced manual abilities in the placebo group. Moreover, children born to mothers who received pravastatin had a higher general mean conceptual ability score (98.2±16.7 vs 89.7±11.0; P=.13) and a lower frequency (15.4% vs 35.7%; P=.38) of having a score of <85 (ie, 1 standard deviation lower than the mean) compared with those in the placebo group. Finally, there was no difference in the parents' report on the Child Behavior Checklist between the 2 groups. CONCLUSION: This study reported on the long-term neuromotor, cognitive, and behavioral outcomes among children exposed to pravastatin in utero during the second and third trimesters of pregnancy. Although the data were limited by the original trial's sample size, no identifiable long-term neurodevelopmental safety signal was evident with the use of pravastatin during pregnancy. This favorable neonatal risk-benefit analysis justifies continued research using pravastatin in clinical trials.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Costantine MM, Clifton RG, Boekhoudt TM, et al. Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero. Am J Obstet Gynecol. 2023. PMID: 36842489. doi:10.1016/j.ajog.2023.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。